Sign In
Buy AUPH
$16.03
+0.250 (+1.58%)
At Close: Jul 13, 2026
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNISÂ
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
01:01pm, Thursday, 02'nd Jul 2026
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
06:01am, Friday, 26'th Jun 2026
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
09:41am, Thursday, 25'th Jun 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
08:11am, Tuesday, 23'rd Jun 2026
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
07:57am, Sunday, 07'th Jun 2026
814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share. The purchase represents 6.66% of Kevin Tang's total
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
08:33am, Thursday, 04'th Jun 2026
Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue g
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
07:00am, Thursday, 04'th Jun 2026
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death.
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
01:22pm, Wednesday, 03'rd Jun 2026
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences
08:30am, Tuesday, 19'th May 2026
Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ:
Parabolic AI rally has bulls eyeing a comeback for this one-time meme metal trade
02:49pm, Monday, 11'th May 2026
Silver prices surged 7% Monday to the highest since March.
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
12:16pm, Thursday, 07'th May 2026
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress.
Aurinia Pharmaceuticals (NASDAQ:AUPH) vs. Cronos Group (NASDAQ:CRON) Financial Comparison
01:12am, Monday, 27'th Apr 2026
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and Cronos Group (NASDAQ: CRON - Get Free Report) are both medical companies, but which is the better investment? We will compare the two compa
